These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25943503)

  • 1. Regulation of Generic Drugs in Japan: the Current Situation and Future Prospects.
    Kuribayashi R; Matsuhama M; Mikami K
    AAPS J; 2015 Sep; 17(5):1312-6. PubMed ID: 25943503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Generic Drug Reviews for Marketing Authorization between Japan and Canada.
    Kuribayashi R; Appleton S
    Drugs R D; 2017 Sep; 17(3):371-379. PubMed ID: 28577294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
    Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
    Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Regulation for Bioequivalence Evaluations of Generic Ophthalmic Dosage Forms in Japan.
    Myoenzono A; Kuribayashi R; Yamaguchi T; Ogawa T; Takagi K
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):697-702. PubMed ID: 32930951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic Drug Product Development in Japan: Regulatory Updates During 2014-2019 and the Future.
    Kasuga M; Kuribayashi R; Ogawa T; Ugi A; Yamaguchi T; Takagi K; Hirota M
    Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):711-719. PubMed ID: 34586614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 8. Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness.
    Kesselheim AS; Gagne JJ
    Drug Saf; 2015 Oct; 38(10):849-53. PubMed ID: 26105011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic drugs: the stalling game.
    Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 11. Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009-2022.
    Kuribayashi R; Nakano A; Hariu A; Kishioka Y; Honda F
    BioDrugs; 2023 Jul; 37(4):443-451. PubMed ID: 37227657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 1.
    Kuhrt K; Chace-Ortiz M
    IDrugs; 2009 Dec; 12(12):760-4. PubMed ID: 19943217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Generic drugs: we must cut pharmaceutical spending but undertaking drug quality].
    Carrillo Norte JA; Postigo Mota S
    Rev Enferm; 2012 Feb; 35(2):10-9. PubMed ID: 22670381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between the Review Time and Various PMDA Consultations in Recent New Drug Approval Cases in Japan.
    Nishiyama K; Toyoshima S; Yamada H; Suzuki H; Nagai N
    Ther Innov Regul Sci; 2018 Nov; 52(6):731-738. PubMed ID: 29714577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Regulation about generics approval].
    Laguna-Goya N; Blázquez-Pérez A; Pozo-Hernández C
    Farm Hosp; 2006; 30(6):379-84. PubMed ID: 17298196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic drugs for the treatment of ocular conditions: changing the treatment landscape.
    Aref AA
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):551-3. PubMed ID: 24957466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-dose combination and single active ingredient drugs: a comparative cost analysis.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):127-34. PubMed ID: 26174631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
    Pruszydlo MG; Quinzler R; Kaltschmidt J; Haefeli WE
    Dtsch Med Wochenschr; 2008 Jul; 133(27):1423-8. PubMed ID: 18592450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial steps in the regulation of generic biological drugs: a comparison of U.S. and Canadian regimes.
    Szeto KJ; Wolanski M
    Food Drug Law J; 2012; 67(2):131-41, i. PubMed ID: 24620416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.